Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from GeneTether Therapeutics, Inc. ( (TSE:GTTX) ) is now available.
GeneTether Therapeutics Inc. has concluded a licensing agreement for STS-201, a promising small molecule for treating soft tissue sarcoma and other cancers, marking a strategic shift toward oncology. Additionally, the company successfully closed a $500,000 non-brokered private placement, highlighting investor confidence and providing funds for regulatory and clinical activities related to STS-201.
More about GeneTether Therapeutics, Inc.
GeneTether Therapeutics Inc. operates in the biotechnology industry, focusing on oncology drug development. Its primary product, STS-201, is a small molecule aimed at treating soft tissue sarcoma and other cancers.
YTD Price Performance: 0%
Average Trading Volume: 7,787
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$3.08M
For an in-depth examination of GTTX stock, go to TipRanks’ Stock Analysis page.
